Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer

被引：0

作者：

Fabio Puglisi

Lorenzo Gerratana

Matteo Lambertini

Marcello Ceppi

Luca Boni

Filippo Montemurro

Stefania Russo

Claudia Bighin

Michelino De Laurentiis

Mario Giuliano

Giancarlo Bisagni

Antonio Durando

Anna Turletti

Ornella Garrone

Andrea Ardizzoni

Teresa Gamucci

Giuseppe Colantuoni

Adriano Gravina

Sabino De Placido

Francesco Cognetti

Lucia Del Mastro

机构：

[1] University of Udine,Department of Medicine (DAME)

[2] Centro di Riferimento Oncologico di Aviano (CRO) IRCCS,Department of Medical Oncology

[3] University of Genoa,Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine

[4] IRCCS Ospedale Policlinico San Martino,Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica

[5] Clinical Epidemiology Unit,Department of Oncology

[6] IRCCS Ospedale Policlinico San Martino,Department of Breast Oncology

[7] Day Hospital Oncologico Multidisciplinare,Department of Clinical Medicine and Surgery

[8] Istituto di Candiolo,Department of Medical Oncology

[9] FPO-IRCCS,Department of Medical Oncology

[10] ASU FC University Hospital,undefined

[11] Oncologia Medica 2,undefined

[12] IRCCS Ospedale Policlinico San Martino,undefined

[13] Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”,undefined

[14] University of Naples Federico II,undefined

[15] AUSL-IRCCS Reggio Emilia,undefined

[16] Breast Unit Ospedale S Anna,undefined

[17] Citta’ della Salute e della Scienza di Torino,undefined

[18] Breast Unit,undefined

[19] ASL Citta’ di Torino,undefined

[20] Breast Unit,undefined

[21] Department of Medical Oncology AO S. Croce e Carle Ospedale di Insegnamento,undefined

[22] Medical Oncology,undefined

[23] S.Orsola University Hospital,undefined

[24] Sandro Pertini Hospital and S. Eugenio Hospital,undefined

[25] ASL Roma2,undefined

[26] Medical Oncology,undefined

[27] Azienda Ospedaliera S Giuseppe Moscati,undefined

[28] Clinical Trial Unit,undefined

[29] Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”,undefined

[30] Istituto Regina Elena per lo Studio e la Cura dei Tumori,undefined

[31] UO Breast Unit,undefined

[32] IRCCS Ospedale Policlinico San Martino,undefined

来源：

npj Breast Cancer | / 7卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

The GIM2 phase III trial demonstrated the benefit of dose-dense chemotherapy in node-positive early breast cancer (eBC). To better define the dose-dense effect in the hormone receptor-positive subgroup, we evaluated its benefit through a composite measure of recurrence risk. We conducted an ancillary analysis of the GIM2 trial evaluating the absolute treatment effect through a composite measure of recurrence risk (CPRS) in patients with hormone receptor-positive HER2-negative eBC. CPRS was estimated through Cox proportional hazards models applied to the different clinicopathological features. The treatment effect was compared to the values of CPRS by using the Sub-population Treatment Effect Pattern Plot (STEPP) process. The Disease-Free Survival (DFS)-oriented STEPP analysis showed distinct patterns of relative treatment effect with respect to CPRS. Overall, 5-year DFS differed across CPRS quartiles ranging from 95.2 to 66.4%. Each CPRS quartile was characterized by a different patients’ composition, especially for age, lymph node involvement, tumor size, estrogen and progesterone receptor expression, and Ki-67. A number needed to treat of 154 and 6 was associated with the lowest and the highest CPRS quartile, respectively. Dose-dense adjuvant chemotherapy showed a consistent benefit in node-positive eBC patients with hormone receptor-positive HER2-negative disease, but its effect varied according to CPRS.

引用

共 27 条

[1]

Hall CS(2016)Prognostic value of circulating tumor cells identified before surgical resection in nonmetastatic breast cancer patients J. Am. Coll. Surg. 223 20-29

[2]

Dieci MV(2013)Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis Ann. Oncol. 24 101-108

[3]

Pérez-Barrios C(2016)Comparison of methods for circulating cell-free DNA isolation using blood from cancer patients: impact on biomarker testing Transl. Lung Cancer Res. 5 665-672

[4]

Chung JH(2017)Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer Ann. Oncol. 28 2866-2873

[5]

Khagi Y(2017)Hypermutated circulating tumor DNA: correlation with response to checkpoint inhibitor–based immunotherapy Clin. Cancer Res. 23 5729-5736

[6]

Bonilla L(2010)Dose-Dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials J. Natl. Cancer Inst. 102 1845-1854

[7]

Petrelli F(2015)Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials Breast Cancer Res. Treat. 151 251-259

[8]

Burnell M(2010)Cyclophosphamide, epirubicin, and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer J. Clin. Oncol. 28 77-82

[9]

Berry DA(2006)Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer J. Am. Med. Assoc. 295 1658-1667

[10]

Del Mastro L(2015)Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2×2 factorial, randomised phase 3 trial Lancet 385 1863-1872

← 1 2 3 →